Market capitalization | $437.73m |
Enterprise Value | $-208.99m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.56 |
EV/Sales (TTM) EV/Sales | -2.15 |
P/S ratio (TTM) P/S ratio | 4.50 |
P/B ratio (TTM) P/B ratio | 0.70 |
Revenue growth (TTM) Revenue growth | 837.56% |
Revenue (TTM) Revenue | $97.24m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
19 Analysts have issued a SAGE Therapeutics, Inc. forecast:
19 Analysts have issued a SAGE Therapeutics, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 97 97 |
838%
838%
|
|
Gross Profit | 93 93 |
1,007%
1,007%
|
|
EBITDA | -448 -448 |
28%
28%
|
EBIT (Operating Income) EBIT | -449 -449 |
28%
28%
|
Net Profit | -446 -446 |
25%
25%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Barry Greene |
Employees | 487 |
Founded | 2010 |
Website | www.sagerx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.